Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four category 1 innovative drugs. Three of these approvals were granted by the National Medical Products Administration (NMPA) in China, and one by the US FDA. The drugs are targeted towards treating kidney and cardiovascular diseases.
NMPA IND Awards:
- JMKX001149: This novel oral anticoagulant is set to be tested as a prophylactic and treatment for venous thromboembolism, a significant condition affecting blood flow in the veins.
- JMKX003142: Developed to treat autosomal dominant polycystic kidney disease (ADPKD), a condition that affects 1.5 million people in China and can lead to end-stage kidney disease if left untreated.
- JMKX003002: Designed to be assessed as a treatment for hyperphosphatemia in end-stage renal disease dialysis patients. JMKX003002 is a latest-generation phosphorus-reducing agent with good oral compliance and high in vitro persistent activity compared to competitors. It is expected to persistently reduce blood phosphorus levels and improve the quality of life for kidney disease patients.
US FDA IND Award:
- JMKX000189: Granted FDA approval to treat acute ischemic stroke, JMKX000189 is described as the world’s first drug of its target to be developed for a stroke indication. The molecule offers a multifaceted approach to stroke treatment by regulating immune cells, maintaining vascular integrity, and reducing brain cell apoptosis.-Fineline Info & Tech
